Get the app
US › Healthcare

GT Biopharma Inc (GTBP)

US · Healthcare · Biotechnology

$7.03-4.48%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Net profit
$-4.5M
EPS
$-0.12
EPS estimate
$-0.08

EPS came in at -0.12 against a street estimate of -0.08 — a miss of 50.0%.

Key statistics

Market cap
$12.1M
Forward P/E
17.3
P/B
3.59
Book value
$2.00
EPS (TTM)
$-147.50
52-week high
$28.75
52-week low
$4.91
50-day MA
$7.19
200-day MA
$10.74
Beta
0.85

Analyst view

Analysts rate GT Biopharma Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $75.00.

Shareholding

Insiders
15.67%
Institutions
4.44%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC0.83%
Geode Capital Management, LLC0.59%
Vanguard Fiduciary Trust Co0.50%
HRT FINANCIAL LLC0.24%
Everhart Financial Group, Inc.0.22%
SRS Capital Advisors Inc0.21%
Opal Wealth Advisors, LLC0.18%
Northern Trust Corp0.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GT Biopharma Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.